Monday, July 07, 2025 2:36:47 PM
On my chart pullback target zone looks 10 area, 9.75 area, 9.50 area.
Resistance now overhead around 10.40... notice the old shoulder peak around 10.00/10.40 from past upwaves. It's a key battle zone here. Support below looks like 9.75/9.50/9.10? Depends on how far down the price manipulators want to take it. And how many downward weeks they can achieve. In past upwaves, lasting 4 weeks... always followed by 4 or more down weeks collapsing the upwave. Maybe this current time in Anavex development marks a new era...poised for approval, closer to the finish line. And a stronger bias looking upward.
Measuring the wave from 7 to 11, you get 9.00 area in the middle. The Fibonacci target zone is basically 9.50/9.00/8.50 area. The shorter picture, from 9 to 11, offers pullback target 10 area, resistance at 10.30/10.40, and support around 9.70 . we might not see prices in the 8's... unless the price manipulators make a strong effort to take it there. They waited until 11 dollars to slam it down. They didn't take down at 9 or at 10. They waited until 11.
Resistance now overhead around 10.40... notice the old shoulder peak around 10.00/10.40 from past upwaves. It's a key battle zone here. Support below looks like 9.75/9.50/9.10? Depends on how far down the price manipulators want to take it. And how many downward weeks they can achieve. In past upwaves, lasting 4 weeks... always followed by 4 or more down weeks collapsing the upwave. Maybe this current time in Anavex development marks a new era...poised for approval, closer to the finish line. And a stronger bias looking upward.
Measuring the wave from 7 to 11, you get 9.00 area in the middle. The Fibonacci target zone is basically 9.50/9.00/8.50 area. The shorter picture, from 9 to 11, offers pullback target 10 area, resistance at 10.30/10.40, and support around 9.70 . we might not see prices in the 8's... unless the price manipulators make a strong effort to take it there. They waited until 11 dollars to slam it down. They didn't take down at 9 or at 10. They waited until 11.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
